secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0000950170-24-069318
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan
--------------------------------------------------------------------------------

- All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.
- Say-on-pay advisory vote approved: 64.0M For, 2.0M Against, 0.01M abstain.
- Equity plan amendments approved to increase share reserve by 5,200,000 common shares: 63.1M For, 2.8M Against.
- KPMG LLP appointed as independent auditor for 2024: 66.7M For, 1.8M Withheld.
- Auditor remuneration authority approved: 65.7M For, 0.39M Against, 0.01M Abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/0000950170-24-069318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/xene-20240604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-069318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer